Physician-first digital medical review

Medeasy
Review.

Evidence for a brighter practice.

Clinical evidence, practical interpretation, and medical innovation for today’s physicians.

Read Latest Issue Browse Articles

Medeasy Review Issue 03 cover: Diabetes, Earlier. — 28 pagesPhysician-firstNovember 2026

Latest issue

November 2026 — Issue 03

Explore Issue

Diabetes, Earlier.

The newest evidence, a changing treatment philosophy, and the realities of Philippine practice.

Explore Issue

Diabetes, Earlier.

Are we protecting organs soon enough? New international evidence. Philippine clinical realities. Decisions that matter from diagnosis.

Read article

Evidence Synthesis5 min read

Septic Shock: Have We Been Giving Too Much Fluid?

Early vasopressors, fluid volumes, and the evidence behind better resuscitation decisions.

Read article

Therapeutic Review4 min read

COPD Beyond Inhalers

Can biologics reach more patients? IL-33 inhibition may extend exacerbation prevention beyond eosinophil-selected trials, but important questions remain.

Read article

View Magazine Download PDFRead online or keep the complete edition.

Recurring departments

Featured clinical insights

Evidence Update

Papers worth knowing, distilled into the finding and the bedside implication.

Explore

Clinical Discovery

Emerging science with enough context to separate promise from proof.

Explore

Practice Changer

Clear pathways for decisions that show up in clinic every day.

Explore

Future Medicine

New diagnostics, therapies, and frameworks shaping tomorrow's care.

Explore

Therapeutic Review

Focused reviews of mechanism, efficacy, safety, and patient selection.

Explore

Tech Check

A clinical lens on wearables, devices, and digital health.

Explore

Evidence Update

Papers Worth Knowing

Selected from November 2026 · Issue 03 Evidence Update — the finding, the caveat, and the clinical implication.

01NEJM Evidence

DAN-RSV: Does Vaccination Prevent Hospitalization?

In a pragmatic, open-label trial of 513,358 adults, RSV-related respiratory hospitalization was 0.16 vs 0.55 events per 1,000 person-years. Estimated effectiveness: 70.3% (95% CI 49.7–83.2).

Clinical takeaway

The absolute reduction was 0.39 events per 1,000 person-years. Consider patient risk, local eligibility and access.

02N Engl J Med

NHS-Galleri: Does Earlier Detection Improve Outcomes?

Among 142,250 participants aged 50–77, stage III–IV incidence across 12 prespecified cancers was not significantly lower after three rounds: incidence rate ratio 1.03 (95% CI 0.92–1.14), P=0.63.

Clinical takeaway

The primary late-stage cancer endpoint was neutral. Better detection alone does not prove better patient outcomes.

03N Engl J Med

Blinatumomab: Replacing Selected Chemotherapy Cycles

In 709 children with newly diagnosed high-risk B-cell ALL, estimated 4-year EFS was 83.0% vs 70.3%; HR 0.51 (95% CI 0.35–0.73). Interim analysis; median follow-up 2.9 years.

Clinical takeaway

Only two selected chemotherapy cycles were replaced. EFS improved, but neurotoxic events were more frequent (12.0% vs 3.2%).

04N Engl J Med

Oveporexton: An Orexin-Based Approach to Narcolepsy Type 1

Two placebo-controlled phase 3 trials enrolled 168 and 105 people. At 12 weeks, MWT sleep-latency change was +14.3 to +19.8 minutes with oveporexton vs −0.4 to −0.8 with placebo.

Clinical takeaway

Wakefulness and cataplexy improved. Urinary frequency and transient insomnia were common; long-term safety remains uncertain.

Explore Evidence Update

Browse the library